Navigation Links
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
Date:3/29/2009

ical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (ID-TLR driven by lack of blood supply).

In addition, the SPIRIT II results demonstrated that XIENCE V continues to outperform TAXUS, with XIENCE V showing continued clinical benefits at three years, including an 88 percent reduction in the risk of cardiac death and a 57 percent reduction in the risk of MACE.

"In the clinical outcomes that matter most, such as heart attack, repeat procedure at the target lesion or death, XIENCE V demonstrated a consistent reduction compared to TAXUS out to three years," said Patrick W. Serruys, M.D., Ph.D., professor of Interventional Cardiology at Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands, and principal investigator of the SPIRIT II clinical trial. "What's even more impressive is that the clinical differences between XIENCE V and TAXUS continue to widen between two and three years, confirming the long-term safety and efficacy of XIENCE V."

In the 300-patient SPIRIT II trial, XIENCE V demonstrated the following key results at three years:

  • An 88 percent reduction in the risk of cardiac death compared to TAXUS (0.5 percent for XIENCE V vs. 4.2 percent for TAXUS, p-value=0.024)*.
  • A 57 percent reduction in the risk of MACE compared to TAXUS (6.4 percent for XIENCE V vs. 14.9 percent for TAXUS, p-value=0.029)*.
  • An observed 52 percent reduction in the risk of heart attacks (MI) compared to TAXUS (3.3 percent for XIENCE V vs. 6.8 percent for TAXUS, p-value=0.20)*.
  • An observed 56 percent reduction in the risk of ID-TLR compared to TAXUS (4.2 percent for XIENCE V vs. 9.4 percent for TAXUS, p-value=0.092)*.
  • No stent thrombosis between two and three years with XIENCE V,
    '/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
6. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
9. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
10. Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
11. New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:6/30/2015)... ... June 30, 2015 , ... In the Spring of 2015, ... in the Sierra Nevada mountains measured zero for the first time since records have ... of one of its most sustained periods of increasing drought.” , In ...
(Date:6/30/2015)... ... ... America is in a health crisis. Today, 4 out of 5 Americans will ... The answer is simple and is at the core of every disease and dysfunction—stress. ... one million patients and, for the first time ever, gives readers and followers 12 ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reliable source for ... Stadium in Provo, Utah. This legendary band has been packing venues for years and ... have also released more than 20 albums in their career. While Journey is known ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... According to ... article, early humans who lived three to four hundred thousand years ago likely ... health. By examining the chemical compounds in fossilized, ancient dental plaque, researchers were able ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, the premier ... own Debby Mann, CPC, RCC, ROCC, Coding Documentation and Education Manager, was honored ... Recognition Award for her contribution to the RBMA Coding Subcommittee. , Ms. ...
Breaking Medicine News(10 mins):Health News:RainSoil launches water-retention product as drought spreads. 2Health News:RainSoil launches water-retention product as drought spreads. 3Health News:12 Easy-To-Follow Steps to Transform Body, Mind and Spirit 2Health News:Journey Tickets at The Stadium of Fire at Lavell Edwards Stadium in Provo, Utah: Ticket Down Slashes Ticket Prices for Journey on the 4th of July in Provo 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2
... research has found that travelers who are prone to ... risk by pulling on a pair of elastic support ... the evidence that compression stockings can prevent deep vein ... condition in which blood coagulates into small clots inside ...
... outcome, when a nurse, nurses an urge to kill. ... profession, was convicted of murdering two patients // and ... General Hospital in Oxfordshire. ,The accused had injected ... caused the patients’ to stop breathing.Geen had committed these ...
... high time somebody spoke of retirement blues. A study ... retirement despondency claims three important factors that measure a ... outlook physical health and pension, in that order. Surprisingly, ... list for a happy retirement. ,The study tracked ...
... Concerns have been raised about the alarming rate of ... According to official estimates, about 6% of Australian children ... ,VicHealth, one of the important health promotion bodies of ... to curb childhood obesity. Additionally, it has pointed out ...
... who develop pre-eclampsia, which are a condition of abnormally high ... a stroke during pregnancy. // But new studies by ... and Prevention now report that pre-eclampsia is also a risk ... Brown and colleagues in Atlanta used data from the Stroke ...
... is better than Tamoxifen in preventing breast cancer in ... said that both drugs reduce the risk of cancer ... trial show that Eli Lilly and Co's Evista, known ... could prompt clinicians to replace Tamoxifen with Evista in ...
Cached Medicine News:Health News:Travel-Related Blood Clots Can Be Reduced By Using Flight Stockings 2
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: